Are you ready to heal the failing heart and rescue its beat? PERM1, a promising protein, paves the way for new treatments for systolic heart failure. The heart, an extraordinary muscle, beats ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...

Living with a heart that struggles to pump effectively creates daily challenges for millions of Americans. Systolic heart failure fundamentally changes how patients experience everyday activities.

It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

Through a deep-learning model, researchers have shown that ordinary ECG images can be leveraged to identify patients with an LV ejection fraction below 40%. Their approach also appears able to ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. The American Heart ...

Patients hospitalized for severe COVID-19 exhibit cardiac systolic dysfunction and small vessel disease at long-term follow-up. This is according to a new study from Karolinska Institutet and ...

Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...